ENTYVIO® Outcomes in Real-world, Bio-naïve Ulcerative Colitis and Crohn’s Disease Patients (EVOLVE)—Greece (EVOLVE-Greece)

First published 19/07/2017

Last updated 23/04/2024

EU PAS number:

EUPAS19669

Study

Finalised

Download as PDF

Documents

Study protocol

Study results

Vedolizumab-5036 - Takeda EVOLVE_redacted

English (145.72 KB - PDF) View document

Study report

Other information

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Conflicts of interest of investigators

GJM CoI

English (10.87 KB - PDF) View document

ENTYVIO® Outcomes in Real-world, Bio-naïve Ulcerative Colitis and Crohn’s Disease Patients (EVOLVE)—Greece (EVOLVE-Greece)

Secondary tabs

Share this page